Inovio Biomedical Corporation in collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania is evaluating DNA vaccine candidates against swine influenza A (H1N1) virus. These vaccines, delivered using Inovio’s proprietary electroporation technology, have the potential to provide protection against a broad scope of existing as well as currently unknown, unmatched influenza strains that could emerge - one of the perpetual challenges in trying to protect against influenza. The purpose of this evaluation is to test these vaccine candidates against pandemic and seasonal influenza strains in animal models and will include testing against a recently identified swine H1N1 strain.
Inovio scientists have created DNA vaccine candidates broadly targeting the H1N1, H2N2, H3N2, and H5N1 influenza sub-types, which make up the majority of seasonal and pandemic influenza.
Mice immunized with an Inovio H1N1 DNA vaccine were challenged with a lethal dose of the unmatched H1N1 virus. All the immunized mice survived the challenge (100% protection) to the end of the experiment and displayed significant protection from infection-associated morbidity. All the control mice died by day 8 after being challenged with the virus.
If you would like to make a comment, please fill out the form below.
Featured Reports
